ARTL

Artelo Biosciences Inc

2.21

Oct 27 • 1:54 PM ET +0.01 (0.45%)

Healthcare Biotechnology USA Nano NASD

Peers: SKYE LEXX SPRC CRBP IGC CMND ENVB SILO PCSA ABVC

Index	-
Market Cap	1.22M
Enterprise Value	-2.93M
Income	-12.67M
Sales	0.00M
Book/sh	10.74
Cash/sh	7.64
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Nov 14, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.21
P/C	0.29
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.00
Current Ratio	3.00
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-206.84
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	16.31% 35.60%
Sales past 3/5Y	- -
EPS Y/Y TTM	59.79%
Sales Y/Y TTM	-
EPS Q/Q	94.68%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	- -

Insider Own	0.06%
Insider Trans	0.00%
Inst Own	2.38%
Inst Trans	-3.39%
ROA	-234.30%
ROE	-705.71%
ROIC	-253.22%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-26.72%
SMA50	-51.32%
SMA200	-90.11%
Trades

Shs Outstand	0.55M
Shs Float	0.55M
Short Float	6.32%
Short Ratio	0.07
Short Interest	0.03M
52W High	179.19 -98.77%
52W Low	2.15 2.79%
Volatility	8.45% 6.87%
ATR (14)	0.45
RSI (14)	26.96
Beta	-0.04
Rel Volume	0.08
Avg Volume	476.74K
Volume	25,918

Perf Week	-15.65%
Perf Month	-48.60%
Perf Quarter	-66.06%
Perf Half Y	-93.12%
Perf YTD	-93.29%
Perf Year	-97.57%
Perf 3Y	-99.01%
Perf 5Y	-99.88%
Perf 10Y	-
Recom	3.00
Target Price	486.00
Prev Close	2.20
Price	2.21
Change %	0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-25	Upgrade	D. Boral Capital	Hold → Buy	$20
Feb-12-21	Initiated	Ladenburg Thalmann	Buy	$7

Oct-26-26 07:55AM	Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain (GlobeNewswire) -13.73%
Oct-07-26 08:48AM	Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform (GlobeNewswire)
Sep-23-26 07:33AM	Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings (GlobeNewswire) +76.14%
Sep-16-26 07:30AM	Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity (GlobeNewswire) -29.78%
Sep-08-26 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
08:00AM	Loading…
Aug-27-26 08:00AM	Artelo Biosciences Announces Reverse Stock Split (GlobeNewswire) -6.98%
Aug-20-26 08:52AM	Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 (GlobeNewswire)
Aug-17-26 08:52AM	Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies (GlobeNewswire) -8.76%
Aug-13-26 08:00AM	Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results (GlobeNewswire)
Aug-10-26 08:47AM	Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma (GlobeNewswire)
Jul-22-26 08:39AM	New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy - Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition (GlobeNewswire)
Jul-16-26 08:48AM	Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions (GlobeNewswire)
Jul-14-26 08:47AM	Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 (GlobeNewswire) +10.48%
Jul-13-26 09:02AM	Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy (GlobeNewswire)
Jul-01-26 08:42AM	Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury (GlobeNewswire)
08:57AM	Loading…
Jun-30-26 08:57AM	Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 (GlobeNewswire)
Jun-29-26 08:45AM	Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 (GlobeNewswire)
Jun-10-26 07:38AM	Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success (GlobeNewswire)
May-14-26 04:05PM	Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results (GlobeNewswire) -21.37%
Apr-28-26 08:25AM	Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development (GlobeNewswire) -5.31%
Apr-20-26 10:30AM	BC-Most Active Stocks (Associated Press)
07:50AM	Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile (GlobeNewswire)
Apr-07-26 07:50AM	Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.29%
Mar-30-26 04:46PM	Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.17% -13.17%
Mar-27-26 10:40AM	Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +230.41%
10:30AM	BC-Most Active Stocks (Associated Press)
Mar-25-26 04:05PM	Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments (GlobeNewswire) -16.23% -34.23%
07:31AM	Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength (GlobeNewswire)
Mar-18-26 08:07AM	Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study (GlobeNewswire) +50.72%
07:41AM	Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients (GlobeNewswire)
08:13AM	Loading…
Mar-07-26 08:13AM	Artelo Biosciences announces 3-for-1 reverse stock split (TipRanks)
Mar-06-26 08:00AM	Artelo Biosciences Announces Reverse Stock Split (GlobeNewswire)
Feb-24-26 08:00AM	Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results (GlobeNewswire)
Dec-23-25 09:00AM	Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate (GlobeNewswire)
Dec-03-25 08:30AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models (GlobeNewswire) -8.33%
Nov-12-25 08:00AM	Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire) -8.16%
Nov-04-25 08:30AM	Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer (GlobeNewswire) -38.00%
Oct-27-25 08:00AM	Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer (GlobeNewswire)
Oct-15-25 09:15AM	Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit (GlobeNewswire)
Oct-01-25 04:05PM	Artelo Biosciences Announces Closing of $2.0 Million Public Offering (GlobeNewswire)
Sep-30-25 08:30AM	Artelo Biosciences Announces Pricing of $2.0 Million Public Offering (GlobeNewswire) -21.54%
Sep-29-25 07:15PM	Artelo Biosciences Announces Proposed Underwritten Public Offering (GlobeNewswire) +6.17%
08:30AM	Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference (GlobeNewswire)
Sep-10-25 08:30AM	Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms (GlobeNewswire)
Sep-08-25 09:49AM	Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls (The Fly)
Sep-05-25 04:05PM	Artelo Biosciences Announces Closing of $3.0 Million Public Offering (GlobeNewswire)
Sep-04-25 08:37AM	Artelo Biosciences Announces Pricing of $3.0 Million Public Offering (GlobeNewswire) -50.34%
Sep-03-25 04:35PM	Artelo Biosciences Announces Proposed Underwritten Public Offering (GlobeNewswire)
11:33AM	Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results (GlobeNewswire)
08:45AM	Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) (GlobeNewswire)
Aug-25-25 07:55AM	Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain (GlobeNewswire)
Aug-13-25 08:00AM	Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-11-25 09:15AM	Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 (GlobeNewswire) +20.12%
Aug-04-25 07:30AM	Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset (GlobeNewswire)
Aug-01-25 07:45AM	Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression (GlobeNewswire) -14.00%
Jul-09-25 07:50AM	Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium (GlobeNewswire) +35.85%
07:20AM	Artelo Biosciences' ART12.11 Shows Promising Antidepressant Effects in Preclinical Study (Insider Monkey)
Jul-07-25 07:45AM	Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model (GlobeNewswire) +42.49%
Jun-30-25 07:45AM	Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain (GlobeNewswire) +95.43%
Jun-26-25 08:00AM	Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing (GlobeNewswire) +12.07%
Jun-11-25 08:30AM	Artelo Biosciences Announces Reverse Stock Split (GlobeNewswire) +6.19%
Jun-05-25 09:00AM	Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study (GlobeNewswire)
Jun-02-25 09:00AM	New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression (GlobeNewswire)
May-13-25 08:00AM	Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-28-25 08:45AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis (GlobeNewswire)
Apr-10-25 05:43AM	New Strong Sell Stocks for April 10th (Zacks) -10.63%
Mar-31-25 08:30AM	Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 (GlobeNewswire) -6.91%
Mar-28-25 03:39AM	New Strong Sell Stocks for March 28th (Zacks)
Mar-03-25 08:00AM	Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results (GlobeNewswire) -6.54%
Feb-14-25 09:00AM	Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex (GlobeNewswire) -14.39%
Feb-11-25 09:00AM	Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland (GlobeNewswire)
Jan-13-25 09:00AM	Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 (GlobeNewswire)
Dec-10-24 09:43AM	Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia (TipRanks)
Dec-09-24 09:15AM	Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia (GlobeNewswire) -5.39%
Nov-18-24 08:30AM	Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit (GlobeNewswire) +17.31%
Nov-13-24 08:30AM	Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium (GlobeNewswire) -5.98%
Nov-12-24 08:00AM	Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.42%
Nov-05-24 08:30AM	Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's Preclinical Screening Platform for Pain Program (GlobeNewswire) +9.66%
Oct-09-24 09:00AM	Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th (GlobeNewswire)
Sep-04-24 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 08:00AM	Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-15-24 08:30AM	Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor (GlobeNewswire)
Jul-03-24 09:00AM	Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jul-02-24 09:00AM	Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform (GlobeNewswire)
Jul-01-24 09:00AM	Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-04-24 08:30AM	Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society (GlobeNewswire)
May-29-24 08:30AM	Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24 (GlobeNewswire)
May-13-24 01:53PM	ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-10-24 09:00AM	Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th (GlobeNewswire)
Apr-23-24 08:30AM	Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy (GlobeNewswire)
Apr-22-24 08:30AM	Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time (GlobeNewswire)
Mar-25-24 01:53PM	ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023 (InvestorPlace)
08:00AM	Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 09:15AM	Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge (GlobeNewswire)
Feb-15-24 09:00AM	Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th (ACCESSWIRE) +6.13%
Jan-23-24 08:30AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy (GlobeNewswire)
Jan-08-24 08:30AM	Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12 (GlobeNewswire)
Dec-05-23 08:30AM	Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire)
Nov-30-23 09:00AM	Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire)

Show Previous News

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

PresidentMr. Gregory D. Gorgas M.B.A.

CFOMr. Mark E. Spring CPA

Senior VP & Chief Scientific OfficerDr. Andrew Yates Ph.D.

Chief Medical OfficerDr. Steven D. Reich M.D.

Senior Vice President of FinanceMr. Jason H. Baybutt

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTL

Artelo Biosciences Inc

Upgrade your Finviz experience